MEDIWOUND LTD (MDWD)
IL0011316309 - Common Stock
Overall MDWD gets a fundamental rating of 3 out of 10. We evaluated MDWD against 197 industry peers in the Pharmaceuticals industry. While MDWD seems to be doing ok healthwise, there are quite some concerns on its profitability. MDWD is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MDWD has reported negative net income.
MDWD had a negative operating cash flow in the past year.
MDWD had negative earnings in 4 of the past 5 years.
In the past 5 years MDWD reported 4 times negative operating cash flow.
1.2 Ratios
MDWD's Return On Assets of -10.10% is fine compared to the rest of the industry. MDWD outperforms 73.85% of its industry peers.
Looking at the Return On Equity, with a value of -21.25%, MDWD is in the better half of the industry, outperforming 72.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.1% | ||
| ROE | -21.25% | ||
| ROIC | N/A |
ROA(3y)-39.31%
ROA(5y)-27.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDWD's Gross Margin of 19.20% is in line compared to the rest of the industry. MDWD outperforms 49.74% of its industry peers.
In the last couple of years the Gross Margin of MDWD has declined.
MDWD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-17.98%
GM growth 5Y-13.05%
2. Health
2.1 Basic Checks
MDWD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MDWD has been increased compared to 1 year ago.
Compared to 5 years ago, MDWD has more shares outstanding
The debt/assets ratio for MDWD is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.64, we must say that MDWD is in the distress zone and has some risk of bankruptcy.
MDWD has a Altman-Z score (-0.64) which is in line with its industry peers.
A Debt/Equity ratio of 0.20 indicates that MDWD is not too dependend on debt financing.
MDWD has a Debt to Equity ratio (0.20) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.64 |
ROIC/WACCN/A
WACC8.89%
2.3 Liquidity
A Current Ratio of 4.59 indicates that MDWD has no problem at all paying its short term obligations.
MDWD has a Current ratio of 4.59. This is in the better half of the industry: MDWD outperforms 62.56% of its industry peers.
MDWD has a Quick Ratio of 4.33. This indicates that MDWD is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MDWD (4.33) is better than 60.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.59 | ||
| Quick Ratio | 4.33 |
3. Growth
3.1 Past
MDWD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.58%, which is quite impressive.
MDWD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -29.48%.
Measured over the past years, MDWD shows a very strong growth in Revenue. The Revenue has been growing by 40.61% on average per year.
EPS 1Y (TTM)79.58%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q83.9%
Revenue 1Y (TTM)-29.48%
Revenue growth 3Y-4.95%
Revenue growth 5Y40.61%
Revenue growth Q2Q-54.06%
3.2 Future
Based on estimates for the next years, MDWD will show a very strong growth in Earnings Per Share. The EPS will grow by 43.10% on average per year.
The Revenue is expected to grow by 46.72% on average over the next years. This is a very strong growth
EPS Next Y-155.66%
EPS Next 2Y-56.97%
EPS Next 3Y29.9%
EPS Next 5Y43.1%
Revenue Next Year28.83%
Revenue Next 2Y30.83%
Revenue Next 3Y42.48%
Revenue Next 5Y46.72%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MDWD. In the last year negative earnings were reported.
Also next year MDWD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as MDWD's earnings are expected to grow with 29.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-56.97%
EPS Next 3Y29.9%
5. Dividend
5.1 Amount
MDWD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MEDIWOUND LTD
NASDAQ:MDWD (5/17/2024, 7:12:34 PM)
16.98
-0.31 (-1.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap161.14M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.1% | ||
| ROE | -21.25% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 19.2% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.59 | ||
| Quick Ratio | 4.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)79.58%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-155.66%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-29.48%
Revenue growth 3Y-4.95%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y